Market Snapshot

S&P Futures
4,114.00
Dow Futures
33,641.00
NASDAQ Futures
13,811.00

18.60$-0.21 -1.12%
At close    04:00 PM   
From: To:

Stock Snapshot

19.74
Prev. Close
18.74
Open
1.68B
Market Cap
6.30M
Number of Shares
18.12
Day Low
18.98
Day High
18.60
-
P/E Ratio
84.97M
Free Float in %
-2.13
EPS 2021
4.63
Book Value per Share
7.71
Cash Flow per Share
FibroGen, Inc. (FGEN)
FibroGen, Inc. (FGEN) stock rallied over -1.12% intraday to trade at $18.60 per share on NASDAQ. The stock opened with a fall of -5.07% at $18.74 and touched an intraday high of $18.98, 3.85% against the last close of $19.74. The stock went to a low of $18.12 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-04-09$18.74$18.57$18.57$18.98$18.124,064,195
2021-04-08$19.36$18.81$18.81$19.86$18.647,225,200
2021-04-07$23.87$19.74$19.74$23.98$19.7120,181,600
2021-04-06$35.32$34.64$34.64$35.80$34.501,877,600
2021-04-05$35.89$35.63$35.63$36.06$34.64504,400
2021-04-01$35.28$35.68$35.68$36.12$34.25900,800
2021-03-31$32.41$34.71$34.71$35.70$32.171,371,300
2021-03-30$31.00$31.11$31.11$32.15$30.881,082,500
2021-03-29$31.39$31.00$31.00$32.15$30.96599,300
2021-03-26$31.30$31.91$31.91$31.96$30.81451,800
2021-03-25$31.15$31.32$31.32$31.80$30.771,156,400
FibroGen, Inc.
409 Illinois Street
San Francisco, CA 94158
United States

http://www.fibrogen.com
415 978 1200
Employees
599
Sector
Healthcare
Sales or Revenue
176.30M
Industry
Biotechnology
5Y Sales Change
-0.50
Fiscal Year Ends
2020-12-30
Mr. James A. Schoeneck
Chairman
Mr. Pat Cotroneo
Chief Financial Officer
Dr. K. Peony Yu
Exec. Advisor to Chief Exec. Officer
FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.